Furthermore, we revealed that the small molecule compound MLN4924 increased KMD5C and subsequently stabilized CRBN, therefore potentiating the antileukemia effect of IMiDs and providing a novel molecular mechanism for the treatment of AML using MLN4924 and IMiDs. The gene discussed is CRBN; the disease is acute myeloid leukemia.